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Abstract
Background: Complete resection of enhancing tumor as assessed by early (<72 hours) postoperative MRI is
regarded as the optimal result in glioblastoma surgery. As yet, there is no consensus on standard procedure if post-
operative imaging reveals unintended tumor remnants.
Objective: The current study evaluated the feasibility and safety of an early re-do surgery aimed at completing
resections with the aid of 5-ALA fluorescence and neuronavigation after detection of enhancing tumor remnants on
post-operative MRI.
Methods: From October 2008 to October 2012 a single center institutional protocol offered a second surgery within
one week to patients with unintentional incomplete glioblastoma resection. We report on the feasibility of the use 5-
ALA fluorescence guidance, the extent of resection (EOR) rates and complications of early re-do surgery.
Results: Nine of 151 patients (6%) with glioblastoma resections had an unintentional tumor remnant with a volume
>0.175 cm3. 5-ALA guided re-do surgery completed the resection (CRET) in all patients without causing neurological
deficits, infections or other complications. Patients who underwent a re-do surgery remained hospitalized between
surgeries, resulting in a mean length of hospital stay of 11 days (range 7-15), compared to 9 days for single surgery
(range 3-23; p=0.147).
Conclusion: Our early re-do protocol led to complete resection of all enhancing tumor in all cases without any new
neurological deficits and thus provides a similar oncological result as intraoperative MRI (iMRI). The repeated use of
5-ALA induced fluorescence, used for identification of small remnants, remains highly sensitive and specific in the
setting of re-do surgery. Early re-do surgery is a feasible and safe strategy to complete unintended subtotal
resections.
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Introduction
The resection of enhancing tumor (gross total resection,
GTR) is known to prolong progression free and overall survival
[1,2]. The introduction of 5-amino levulinic acid (5-ALA) as an
intra-operative tumor detection agent significantly increases the
likelihood of achieving a GTR, which previously was only
achieved in a minority of patients [3-6]. Furthermore, intra-
operative electrophysiological function surveillance
technologies for mapping and monitoring of motor, speech, and
visual functions have helped to increase resection of
glioblastoma adjacent to areas of presumed eloquence [7-10].
An early post-operative MRI (within 72 hours) is commonly
used to verify whether a complete resection of enhancing
tumor has been achieved [3]. Using MRI during surgery
(intraoperative MRI, iMRI) allows assessment of the extent of
resection prior to the end of anesthesia, and thus provides the
possibility to restart tumor surgery and resect any detected
tumor remnants [11-15]. A recent randomized controlled trial
showed an increased rate of achieved GTR using iMRI
compared to surgeries without iMRI (96% achieved GTR with
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iMRI versus 68% without iMRI, no 5-ALA used) [16], thus
confirming the advantage of iMRI for improving the extent of
resection in surgery for malignant glioma.
iMRI differs from postoperative MRI not only in the timing of
imaging (during surgery versus after surgery), but mainly in the
consequences drawn from image findings; tumor remnants
visualized through iMRI may lead to further resection if located
in ineloquent locations, whereas small remnants seen on
postoperative MRI seldom lead to a second surgery with
immediate resection [1,16].
In the absence of iMRI our institution follows a protocol in
which patients with contrast enhancing tumor remnants in
presumed non-eloquent locations are offered an early re-
operation (re-do surgery) in order to obtain the optimal surgical
result. We used neuronavigation for intraoperative guidance
and 5-ALA for identification of the tumor remnant that eluded
resection in the initial surgery. This report describes the burden
for the patient, neurological deficits and EOR, as well as the
value of 5-ALA and neuronavigation in the setting of early re-do
surgery.
Materials and Methods
Patients
All patients operated upon between October 2008 and
October 2012 were retrospectively screened for study
inclusion. Inclusion criteria were (i) initially CRET eligible tumor,
(ii) attempted CRET at the Department of Neurosurgery, Bern
University Hospital, Switzerland, at initial surgery, (iii) diagnosis
of glioblastoma based on histology and (iv) a CRET eligible
tumor remnant >0.175 cm3 according to postoperative MRI.
Demographics and presenting symptoms were retrieved from
our prospectively managed tumor database as well as
operative and hospital records. All patients were assessed
neurologically based on National Institutes of Health Stroke
Scale (NIHSS) on the day before surgery, and at 24 hours, 48
hours, and 3 months after surgery. New postoperative
neurological deficits were regarded as permanent if they
persisted at 3 months. The study was approved by the local
Ethics committee (Kantonale Ethikkommission Bern;
registration number 14-11-12). The Kantonale Ethikkommission
Bern waived the need for a patient informed consent because
the retrospectively-collected data was analyzed anonymously.
Preoperative Imaging
All pre- and postoperative MRIs were performed on a 1.5- or
a 3-T scanner with a head coil. Unenhanced and enhanced
(magnetization-prepared rapid-acquisition gradient
echocardiography sequences with 0.1 mmol/kg body weight
gadolinium-DTPA given intravenously) T1 sequences without
gap were obtained (256 x 256 matrix, rectangular field of view,
1-mm slice thickness).
Surgery, 5-ALA and intra-operative mapping and
monitoring
Surgery was performed as previously published [9]. In brief,
neuronavigation (Brainlab) and 5-ALA were used per protocol.
Neuronavigation was used for planning, choosing the trajectory
and initial guidance during surgery. Resection was completed
according to 5-ALA-induced fluorescence. Intra-operative
monitoring and mapping was used depending on the presumed
eloquency of the tissue adjacent to the tumor, as previously
published [8].
Postoperative imaging and early re-do surgery
Postoperative MRI was scrutinized for contrast enhancing
tumor remnants. Volumetric analysis through manual
segmentation of the contrast enhancing tumor remnant was
performed across all slices (VectorVision; Brainlab,
Heimstetten, Germany) [9]. Patients with resectable tumor
remnant >0.175 cm3 were informed of the potential benefit of a
complete resection of enhancing tumor (CRET) and were
offered a second intervention within a few days (re-do surgery).
Peri-operative antibiotic prophylaxis was extended from
single shot Cefuroxim 1.5g iv for initial surgery to Cefuroxim
1.5g iv every 8 hours for re-do surgery.
Re-do surgery was performed using the same protocol as
the first surgery. Neuronavigation was used to guide the
surgical approach towards the small tumor remnant. Tumor
remnant was identified through 5-ALA-induced fluorescence
under blue light, resected and sent for histological confirmation
(Figure 1). The postoperative MRI after second surgery was
analyzed with consideration of the elapsed time after initial
surgery; only the site of tumor remnant was investigated for
remnants in order not to confuse remnants with postoperative
inflammation [3]. Volumetric analysis of tumor remnant after re-
do surgery was identical to the analysis after initial surgery. A
re-do resection was judged CRET if the enhancing tumor
remnant after initial surgery had vanished on post-operative
MRI.
Follow up examination
All patients were assessed using the NIHSS prior to
discharge after the second surgery and again at a 3-month
follow-up consultation. New postoperative neurological deficits
were regarded as permanent if they persisted at 3 months.
Hospital records were scrutinized for perioperative
complications. In addition, patients were interviewed at follow-
up regarding the occurrence of peri-operative complications.
Results
Initial Surgery
A total of 208 glioblastomas were operated upon from
October 2008 to October 2012. Enhancing tumor tissue
remnant with a volume of >0.175 cm3 that was left
unintentionally was detected in the postoperative MRI of 9
patients (Table 1). Histological analysis was obtained in 7
patients. Solid or infiltrating tumor tissue was confirmed in 2
cases (patients 2 and 4) and 5 cases (#1, 3, 5, 8 and 9),
respectively. Of these, 3 patients were female and the mean
age was 63 years (range 38 - 78 years; Table 1).
Neuronavigation had been used in all cases, 5-ALA in all but 1
case, and intra-operative mapping (IOM) had been used in 5 of
Early Re-Do Surgery for Glioblastoma
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the 9 patients. All tumors affected only one lobe: the frontal
lobe in 4, the parietal lobe in 3 and the temporal lobe in 2
patients. The tumor was located on the right side in 7 patients.
In 5 of the 9 patients the contrast enhancing tumor was within
10 mm of a presumed eloquent structure according to pre-
operative MRI (CST in 4 patients and arcuate fascicle in 1
patient). One patient with a tumor near a presumed speech
area was operated upon while awake to allow speech mapping.
At the end of the surgery in all cases, the surgeon was certain
that a complete resection had been achieved. Post-operative
MRI was performed on the first day after surgery in all patients.
A comparison to the initial pre-operative MRI revealed that the
tumor remnants were not new lesions but in fact part of the
initial tumor. Mean tumor volumes before and after first surgery
were 24.3 cc (range 1.6 - 48.7 cc) and 1.0 cc (range 0.2-4.9
cc), respectively. The mean EOR of the first surgery ranged
from 39% to 99% (median 98%).
One patient had a left-sided neglect after the first surgery,
which persisted at the 3-month follow-up consultation. In all
remaining patients, we observed no new neurological deficits
after initial surgery and re-do procedure, nor at the 3-months
post-operative control. No patients had a record of post-
operative pneumonia, deep vein thrombosis, pulmonary
embolism, hepatic failure, wound infections, skin healing issues
or other medical problems.
Re-do Surgery
Our offer to re-do surgery to optimize the surgical result was
accepted by all 9 patients. Re-do surgery was scheduled and
performed within 7 days after the first surgery (mean elapsed
time: 4 days, range 2-7 days). Neuronavigation and 5-ALA
were used in all re-do surgeries (Table 2). According to the
surgeon neuronavigation was useful in all cases for guidance
of surgery towards the tumor remnant. 5-ALA-induced red
fluorescence revealed the tumor remnant in 7 cases; in one
case 5-ALA fluorescence was weak and not useful according to
the surgeon, and in one case fluorescence was not reported. A
new, patchy pink fluorescence was observed in 2 patients
(patients 5 and 7).
The second surgery was significantly shorter than the first
surgery (mean 244 minutes for initial surgery [SD 115] versus
111 minutes [SD 39] for redo surgery, p ≤0.005, Student`s t-
test).
Re-do surgeries were generally performed by the same
surgeon that performed the first surgery. In 4 cases the tumor
remnant was found behind a 5-ALA negative parenchyma
Figure 1.  Navigation guides the approach and 5-ALA fluorescence identifies tumor remnant during re-do surgery.  (A)
Intraoperative neuronavigation guides the surgical approach towards the contrast enhancing tumor remnant (green crosslines =
pointer navigation). (B) White light inspection of the surgical cavity. (C) 5-ALA induced fluorescence reveals tumor remnant under
blue light (arrow).
doi: 10.1371/journal.pone.0079846.g001
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bridge during re-do surgery (Table 2). In the patient who had
initially been operated upon without 5-ALA (patient 2),
unsuspicious parenchyma separated the tumor remnant from
the cavity. No specific reason for missing the 5-ALA positive
tissue was determined in the remaining 4 cases.
Patients remained hospitalized between surgeries. The
mean durations of hospital stays among the 9 patients
undergoing re-do surgery and the 142 patients undergoing a
single resection were 11 days (range 7-15) and 9 days (range
3-23; p=0.147) respectively. We observed no elevated liver
enzymes after the first or second administration of 5-ALA. No
Table 1. Demographics and specifications of initial and re-do surgeries.
Demographics 1st Surgery Re-do Surgery
Patient
no.
Age
(years) Sex   
Locali-
zation   
Initial
volume
(cm3)   
Duration
of surgery
(min)
Intra-
operative
monitoring
Residual
volume
(cm3) EOR (%)
Days
between
surgeries
Duration of
surgery
(minutes)
Intraoperative
monitoring
EOR
(%)   
Duration
of stay
(days)
1 76 f TemporalRight 10.69 282 none 0.22 98 4 190 none 100% 14
2 61 m ParietalRight 19.12 150 none 4.92 74 5 60 none 100% 15
3 73 m TemporalRight 39.42 342 none 0.28 99 3 135 none 100% 8
4 58 f FrontalRight 1.58 78 none 0.97 39 2 120 none 100% 9
5 65 m Frontal Left 19.16 453
MEP,
Speech
(awake) and
motor
mapping
0.53 97 6 78 MEP, SSEP 100% 10
6 38 m FrontalRight 12.91 211
MEP, SSEP,
motor
mapping
0.30 98 7 100 MEP, SSEP 100% 15
7 78 m ParietalRight 48.66 177 MEP, SSEP 0.28 99 6 126 MEP, SSEP 100% 11
8 50 f FrontalRight 44.13 315
MEP, motor
mapping 0.89 98 2 81 MEP, SSEP 100% 7
9 67 m Parietal Left 22.68 186 none 0.62 89 2 107 none 100% 14
Mean 63   24.26 244  1.00 98(median) 4 111  100% 11
Range 38-78   1.58-48.66 78-453  0.22-4.92 38.8-99.4 2-7 78-190  100% 7-15
EOR, extent of resection; f, female; m, male; MEP, Maximum evoked potential; SSEP, Somatosensory evoked potential
doi: 10.1371/journal.pone.0079846.t001
Table 2. Value of neuronavigation and 5-ALA in identifying tumor remnants.
Patient no.   Value of Neuronavigation Value of 5-ALA Histology Reason for incomplete 1st resection
1 Guided surgery Identified remnant Infiltrating tumor Not specified
2 Guided surgery Not specified Solid tumor Remnant hidden by unsuspicious parenchyma
3 Guided surgery and identified tumor Minimal; fluorescence was not specific Infiltrating tumor Not specified
4 Guided surgery Identified remnant Solid tumor Remnant hidden by 5-ALA negative parenchyma
5 Guided surgery Identified remnant and new unspecificfluorescence in resection cavity Infiltrating tumor Not specified
6 Guided surgery Identified remnant No histology obtained Remnant hidden by 5-ALA negative parenchyma
7 Guided surgery Identified remnant and new unspecificfluorescence in resection cavity No histology obtained Remnant hidden by 5-ALA negative parenchyma
8 Guided surgery Identified remnant Infiltrating tumor Remnant hidden by 5-ALA negative parenchyma
9 Guided surgery Identified remnant Infiltrating tumor Not specified
doi: 10.1371/journal.pone.0079846.t002
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new neurologic deficits were observed in the 9 patients at
discharge and at the 3-month follow-up consultation, except for
one patient (patient 7) who experienced a persisting left-sided
neglect after the first surgery.
Complications
One patient had a left-sided neglect after the first surgery,
which persisted at the 3-month follow-up consultation. In all
remaining patients, we observed no new neurological deficits
after initial surgery and re-do procedure, nor at the 3-months
post-operative control. No patients had any record of post-
operative pneumonia, deep vein thrombosis, pulmonary
embolism, hepatic failure, wound infection, skin healing issues
or other medical problems.
Discussion
Landmark publications in recent years provided convincing
evidence that the complete removal of enhancing tumor
produces the optimal surgical result for patients suffering from
glioblastoma [1,2,16,17]. The scientific focus has thus shifted
from the importance of complete resection towards the value of
technologies and surgical strategies that aid achievement of
complete resections. A recent randomized controlled trial on
intraoperative MRI (iMRI) for glioblastoma surgery showed not
only an increased rate of achieved gross total resections, but
also indicated that patients who underwent a complete tumor
resection might have a longer progression-free survival than
patients with residual tumor [16]. Our protocol with early re-do
surgery for unintended tumor remnants resembles the
mentioned iMRI protocol in its ambition to provide complete
resection; its main difference is the timing of imaging and
remnant surgery.
Combined use of 5-ALA and neuronavigation for early
re-do surgery
Detection of tumor remnants during re-do surgery may be a
challenge given the small size of the remnants (mean 1 cc) and
the fact that the remnants were overlooked during the first
surgery. A combination of neuronavigation and 5-ALA-
fluorescence was therefore applied in our series to reliably
detect and resect tumor remnants. There are no reports on
using 5-ALA for early re-do surgery to our knowledge, and 5-
ALA should thus be used with caution. 5-ALA has a plasma
half-life of less than 1 hour and cannot be detected after >6
hours in healthy brain tissue. However, the pharmacokinetics of
5-ALA in glioblastoma infiltrated tissue are not yet entirely
understood, and prolonged leakage of 5-ALA from residual
tumor cells may decrease 5-ALA’s specificity [18,19].
Furthermore, despite its high specificity for glioma tissue [20]
there have been sporadic reports of non-specific, false positive
fluorescence probably caused by inflammation [21-23]. This is
of particular concern in the early post-operative setting as
reparative processes lead to local edema and inflammation.
Non-specific inflammatory processes at the resection border
may also lead to a partial breakdown of the blood brain barrier
as visualized by non-specific contrast enhancement on post-
operative MRI performed >72 hours after surgery [3]. In two of
our patients (#5 and #7, both re-operated after 6 days) a new
pink fluorescence was detected in the resection cavity in
addition to the bright red fluorescence of the tumor remnant
under blue light. We believe that the interval between surgeries
(6 days) was too short for actual tumor recurrence, and thus
suspect that this new fluorescence is non-specific. Hence, we
believe that 5-ALA must be used with caution in early re-do
surgery and the possibility of unspecific fluorescence should
always be considered. Combining 5-ALA with neuronavigation
helped to verify suspected tumor remnants in our series and to
rule out false positive fluorescence; histological analysis
revealed solid or infiltrating tumor in all included cases (Table
2, Figure 2). Therefore, despite a decreased specificity, 5-ALA
retained its value for intraoperative tumor identification even in
those cases where new unspecific fluorescence was observed.
Infections and Complications
Infections are a major concern after re-operations.
Performing a second surgery within a few days entails re-
opening the skin prior to proper healing, which may facilitate
infections. While there are no reports on infections after early
re-do surgery for glioma, there are data on infections for
resection of recurrent glioma. The Glioma Outcome Project
reported an increased rate of general infections after surgery
for recurrent glioblastoma (4.4%, compared to 0% after first
surgery, p<0.0001) [24], according to the authors possibly due
to prolonged use of corticosteroids. The reported rates of local
infections, however, were similar after craniotomy for initial and
recurrent tumor [24]. The absence of infections in our series is
thus in line with the existing literature.
Similarly, our concern that the physical stress of a second
surgery within a short time period might lead to a higher rate of
medical complications turned out to be unfounded for this
series, as we observed no medical complications and no
wound healing problems in the peri-operative period up to 3
months after surgery.
The small sample size of our study does not allow an
extrapolated analysis of infections and complications. Larger
studies are warranted to assess the true rate of infections and
complications for two consecutive surgeries within a short time
interval as described in this study.
Burden of re-do surgery compared to iMRI
Our protocol with early re-do surgery requires a second
anesthesia and may increase patients’ physical and
psychological stress. However, this additional stress was only
necessary in a minority of our patients (9 out of 208 patients,
4.3%). This contrasts with the use of iMRI; in a recent
randomized controlled trial iMRI led to further resection in one-
third of all patients [16]. Thus, anesthesia was prolonged
without apparent benefit to two-thirds of all patients (429 min
for iMRI vs 362 min in conventional group, p=0.007) [16]. Of
note, 5-ALA was not used in the mentioned computed
tomography on iMRI but is administered per protocol to all
patients with presumed glioblastoma at our institution. 5-ALA’s
ability to increase the likelihood of complete resection may
explain the higher rate of incomplete resection before control
MRI in the computed tomography on iMRI as compared to our
Early Re-Do Surgery for Glioblastoma
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series. The ‘number to scan’ to achieve surgical improvement
through iMRI in a single patient may well be higher when using
5-ALA. A protocol of early re-do surgery thus leads to a greater
burden for a small percentage of patients, while routine iMRI
imposes a small additional burden on all patients.
Conclusion
Re-thinking the efforts to achieve a complete resection of
enhancing tumor is warranted in the wake of the 5-ALA study
group`s assessment of the effect of GTR on survival. Providing
glioblastoma patients with a MRI-controlled optimal surgical
result should not be a privilege of centers with intra-operative
MRI. In the absence of iMRI, our institutional protocol calls for
early re-do surgeries (within a week) for unintentional
incomplete resection as detected by early postoperative MRI.
Re-do surgery achieved a complete resection (CRET) in all
patients without leading to additional neurological deficits. A
combination of neuronavigation for surgical guidance and 5-
ALA for tumor identification enabled reliable detection and
removal of tumor remnants in all cases. For neurosurgical
centers that cannot provide iMRI, early re-do surgery may thus
be a feasible strategy to increase the rate of complete
resections in glioblastoma patients.
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